GenScript Says AI Drug Discovery Orders Earn Gross Margins About 20 Points Above Traditional Work as It Lifts Life Science Guidance
First-half 2026 results call, August 16, 2026: revenue up 27.3% to $404.2 million, adjusted net profit up 203%
The most useful disclosure from GenScript's interim call was a number rather than a narrative. CFO Phil Zhao said orders tied to AI-driven drug discovery (AIDD) "run roughly 20 percentage points higher in gross margin than traditional protein expression orders." Management gave three reasons. Orders are larger and spread fixed costs over more volume. Customers pay a premium for speed. And the deliverable is structured, model-ready experimental data rather than protein alone. Zhao argued the premium is durable and could widen as automation matures and utilization rises. That claim is untested at this scale, and the company did not say how much of the first-half mix AIDD already represents. The 20-point gap still explains much of the margin step-up in the Life Science Group (LSG), and it is the central variable for the second half.
Margins Doubled at LSG, With a Tariff Asterisk
Group revenue reached $404.2 million, up 27.3%. Gross profit rose 48% to $206.7 million, and adjusted net profit grew 203.3% to $62.5 million, a record for any half. LSG revenue grew 28.8% to $319 million, about 10 points above the company's initial guidance. Adjusted operating profit rose 102.8% to $94 million, and adjusted operating margin reached 29.5%.
Investors should note that reported margins benefited from U.S. tariff refunds. Excluding them, adjusted gross margin was 55.4% rather than 57.8%, and adjusted operating margin was 27.1% rather than 29.5%. The underlying improvement is still large, but the headline figures flatter the run rate. Management attributed the leverage to years of spending on automation and capacity. About 60% of labs now have AI-driven automated workstations, and the return on the gene-to-protein platform rose 1.5x year over year. Gene-to-protein products and services account for roughly two-thirds of LSG revenue. North America contributes about 50% of the total, Asia Pacific 29% and Europe 21%, and pharma and biotech customers make up more than 80%.
Management Takes Aim at Twist
In response to a JPMorgan question on Twist Bioscience, Ray Chen, President of the Life Science Group, made the most direct competitive claims of the call. He said GenScript captures "more than twice the revenue per delivered item" and that the gap is widening. He said the company processes more than 4,000 designs per day, against "thousands per week" for Twist. He put turnaround from digital sequence to binding data at 4 to 7 days, against more than 2 weeks reported elsewhere. He also cited assay variability under 10%, against close to 30% in a recent customer evaluation of the competitor's workflow.
These are management's figures, drawn from selected customer rounds and public reports, and they have not been independently verified. The strategic argument is more durable than any single data point. Chen said many rivals "stop just at DNA or fragments," while GenScript delivers sequence through expression to model-ready data. He also said modular workstations let GenScript add capacity with lower capital intensity, and that the company is targeting a doubling of throughput every quarter. That is an aggressive goal. Goldman Sachs asked about current utilization and how protein-side capacity, which is less automated than gene synthesis, would scale. The question went unanswered in substance, and the reply was that no one else in the world could accept orders of this magnitude.
What AI-Native Customers Actually Buy
Responding to Morgan Stanley, Chen described a customer base that behaves differently from traditional pharma. A conventional program advances a handful of candidates, while AI-native customers generate hundreds or thousands of sequences per iteration and need results in days. Their molecules are also more complex. Chen's framing was that "we are delivering the data. The data is the end goal," which makes GenScript "part of the customers' AI development infrastructure." If that holds, validation shifts from one-off projects to recurring demand with longer customer lifetimes. The risk is concentration and bargaining power if large model developers eventually build validation capacity in-house. Management did not address that.
Management expects AIDD orders to double in the second half and to sustain "hyper-growth" for several years. It has not disclosed the current AIDD revenue base, which makes that forecast hard to size.
Guidance Raised, Though Not Dramatically
LSG revenue growth guidance is now 25% to 30%, with adjusted gross margin above 55% and adjusted operating margin above 25%. First-half performance is at or above the top of those ranges, so the guidance implies little or no further margin expansion and some moderation in growth. Chen said guidance is being managed "prudently" and that continued trends point to "real potential for continued upside."
ProBio: Orders Outrun Revenue, but AIDD Is Still Small
ProBio revenue grew 34.2% to $61.1 million. Biologics grew 44.2% and advanced therapies 16.3%. New orders rose 54%, with biologics up 62.1% and advanced therapies up 34.9%. By geography, orders rose 73.8% in China and 45.3% internationally. Adjusted gross profit reached $8.3 million, against about $2.7 million a year earlier, and the adjusted EBITDA loss narrowed to $6.5 million from $16.8 million. Management reiterated positive EBITDA in 2027 and raised full-year revenue growth guidance to 25% to 30%. That range implies a slowdown from the first-half pace, even with orders running well ahead of revenue.
ProBio's AIDD exposure is early. CEO Allen Guo said the unit signed $9.7 million of AIDD-related orders in the first half and recognized about $2.5 million of revenue. He described capabilities to move AI-generated candidates to a preclinical candidate in as little as 4 months and from cell transfection to toxicology batch in as little as 4.5 months, even for complex bispecific and trispecific formats. The call positioned AIDD as a future ProBio growth engine, but today it is small against $61.1 million of revenue.
Capital Spending and Balance Sheet
First-half capital expenditure was $48.4 million, and full-year spending is expected at about $130 million. GenScript holds roughly $830 million in cash and cash equivalents. Zhao said the company sees "no need for equity financing," which addresses the Jefferies question on fundraising. Free cash flow and working capital improved year over year, though no figures were given.
Bestzyme: Growth Is Modest and Losses Widened
Bestzyme is the weakest segment. Revenue grew 7.4% to $30.4 million, and adjusted gross profit rose 14% to $13 million. Adjusted R&D spending was $5.6 million, and the adjusted operating loss widened to $1.3 million from $0.6 million. Guidance is for 8% to 10% revenue growth and gross margin above 43%.
The AI case here is about R&D productivity rather than near-term revenue. General Manager Aixi Bai said AI-driven multi-property optimization has doubled the positive hit rate versus 2025. Some projects reach their goals in two design rounds with fewer than 150 mutants. The company expects to deliver 6 to 7 projects in 2026, twice the 2025 count, and says new design and agent platforms cut R&D time by 20%. Gross margins on two products rose 7 and 6 points respectively. Sweet protein commercialization is the key product catalyst, but management gave no timing or sizing.